Neuromodulator / Galderma · Ipsen
Azzalure
AbobotulinumtoxinA: distinguish line improvement, patient satisfaction and the timing of each outcome.
Product Atlas · September 2026
The exact product comes first
Scope of this monograph#
Clinical summary: UK Azzalure. Dysport is a regional discovery relationship, not an interchangeable label.
Clinical statements below summarize the attached documents. They are not a complete prescribing label. Match the exact local product and current instructions to the clinical decision.
Composition & formulation#
A botulinum toxin type A haemagglutinin complex supplied as 125 Speywood units per vial for reconstitution.[3]
How it works#
Reduces acetylcholine release at the neuromuscular junction, producing a temporary reduction in targeted muscle activity.[3]
Indications & treatment areas#
UK labeling covers moderate-to-severe glabellar and/or lateral canthal lines in adults under 65 when the lines have an important psychological impact.[3]
Application considerations#
Use the Azzalure-specific reconstitution and administration instructions. Speywood units are not interchangeable with other toxin units.[3]
Contraindications & precautions#
Hypersensitivity, injection-site infection and specified neuromuscular disorders are contraindications. Review swallowing disorders, muscle weakness and medicines affecting neuromuscular transmission.[3]
Adverse effects & safety#
Local reactions, headache and ptosis may occur. Rare distant toxin effects can involve serious swallowing or respiratory difficulty.[3]
Duration & follow-up#
In a 300-person trial, 60% had at least one-grade improvement at day 120 and 45% at day 150. Satisfaction is a separate outcome.[5]
Distinctions that matter#
The UK label requires at least three months between treatments; that minimum interval is not a promise of effect duration.[3]
Four markets. Separate evidence.#
Documents below identify what has been attached in this research edition. “Source needed” means unverified here; it is not a statement that a product is unapproved.
German Fachinformation is attached; consult its exact presentation and indication wording.[4]
UK SmPC attached for the 125 Speywood-unit presentation.[3]
US prescribing information identifies the glabellar indication in adults under 65. It does not extend UK Azzalure labeling.[1]
TGA assessment documents the Australian toxin presentations. This historical report is not the current local PI.[2]
Studies worth a closer look.#
Improvement and satisfaction follow different curves.
Always state which outcome remains improved at the quoted timepoint.
Follow the evidence.#
Retrieved 6 September 2026. A retrieval date does not establish that an older document is the latest approved revision. Studies marked “abstract” have not completed full-text appraisal.
- [1] DYSPORT US prescribing information ↗Ipsen / DailyMed · label · Document accessed · Checked 2026-09-06
- [2] DYSPORT Australian public assessment report ↗Therapeutic Goods Administration · regulator · Document accessed · Document: April 2021 — historical assessment · Checked 2026-09-06
- [3] Azzalure Summary of Product Characteristics ↗Galderma / emc · label · Document accessed · Checked 2026-09-06
- [4] Azzalure German Fachinformation ↗Galderma / Fachinfo · label · Document accessed · Document: December 2025 · Checked 2026-09-06
- [5] Monheit et al. — abobotulinumtoxinA response and satisfaction ↗Dermatologic Surgery, 2020 · PMID 31356432 · study · Abstract accessed · Checked 2026-09-06
Cite this monograph#
Aesthetic Pass. Azzalure. Product Atlas research edition 2026.09.06.1. https://aestheticpass.com/products/monographs/azzalure/